Proprio, a Seattle-based surgical technology company, achieved a significant milestone this year when its flagship surgical navigation platform, Paradigm™ obtained FDA 510(k) clearance. Paradigm, the company says, harnesses the power of light field technology and artificial intelligence (AI) to generate a real-time 3D visualization of surgery. It provides surgeons with Volumetric Intelligence™, which combines medical images with live data from the platform’s sensor suite.
The system eliminates the need for intraoperative scans, reducing radiation exposure to the patient and surgical staff. Proprio says this saves up to 30 minutes per procedure, increasing the availability of care to patients. By quickly registering imaging data to the anatomy within surgical workflows, Paradigm delivers a high degree of accuracy and enables surgeons to maintain focus on the patient.
“Our unique approach to surgical navigation combines the power of AI with advanced imaging sensors and light field technology,” Gabriel Jones, CEO and co-founder of Proprio says. “By leveraging AI’s data analysis and predictive learning capabilities, the Paradigm system merges views from multimodal sensors and cameras, creating a real-time 3D view of patient’s anatomy, ultimately enabling surgeons to more precisely and efficiently navigate the surgical environment.”
The system’s live, 3D, multimodal data differs greatly from current static approaches to surgical navigation, and the company plans to apply its technology to many surgical specialties beyond its first targets in spine procedures.
Proprio recently secured $43 million in Series B funding from new and existing investors. The capital fuels commercialization to address significant demand for the AI-driven surgical navigation platform.
“For some time, we have been searching for a company that has the potential to disrupt traditional medical device businesses at scale with data, says Alf Grunwald, executive advisor of Bird B. AG, a global investment partnership with significant surgical software and medical device investments in both public and private markets. “Proprio represents that kind of opportunity, and we are honored to join the investment group.”
“We are just beginning to reveal the potential applications of Proprio’s technology and data,” says Jones. “This investment arrives at a pivotal moment, as we perform our first-in-human cases and bring Paradigm to patients around the world. Together, these milestones are a testament to the unparalleled capabilities of the Proprio Paradigm and its potential to revolutionize surgery.”
Editor and Director of Medical Content